Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06775379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Study acronym: X-NOVA2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 46 → 51 locationsv7
  2. Eligibility criteria expanded, about 6 words Secondary endpoints: 3 to 4v6 Show 1 more changeShow less
    • Secondary endpoints: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 40 to 46v5
  4. Study sites: 19 to 40v4
  5. Study sites: 8 to 19v3
  6. Study sites: 4 to 8v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Trial Details
NCT Number NCT06775379
Lead Sponsor Xenon Pharmaceuticals Inc.
Conditions Major Depressive Disorder
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov